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Cystic fibrosis (CF) lung disease is characterized by early and persistent mucus
accumulation and neutrophilic inflammation in the distal airways. Identification of the factors
in CF mucopurulent secretions that perpetuate CF mucoinflammation may provide
strategies for novel CF pharmacotherapies. We show that IL-1b, with IL-1a, dominated the
mucin prosecretory activities of supernatants of airway mucopurulent secretions (SAMS).
Like SAMS, IL-1b alone induced MUC5B and MUC5AC protein secretion and mucus
hyperconcentration in CF human bronchial epithelial (HBE) cells. Mechanistically, IL-1b
induced the sterile a motif–pointed domain containing ETS transcription factor (SPDEF)
and downstream endoplasmic reticulum to nucleus signaling 2 (ERN2) to upregulate mucin
gene expression. Increased mRNA levels of IL1B, SPDEF, and ERN2 were associated with
increased MUC5B and MUC5AC expression in the distal airways of excised CF lungs.
Administration of an IL-1 receptor antagonist (IL-1Ra) blocked SAMS-induced expression of
mucins and proinflammatory mediators in CF HBE cells. In conclusion, IL-1a and IL-1b are
upstream components of a signaling pathway, including IL-1R1 and downstream SPDEF
and ERN2, that generate a positive feedback cycle capable of producing persistent mucus
hyperconcentration and IL-1a and/or IL-1b–mediated neutrophilic inflammation in the
absence of infection in CF airways. Targeting this pathway therapeutically may ameliorate
mucus obstruction and inflammation-induced structural damage in young CF children.
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Introduction
Beginning soon after birth, cystic fibrosis (CF) lung disease is 
characterized by a heterogeneous, persistent mucoinflammatory 
environment. Abnormal airway epithelial ion transport predispos-
es the CF neonatal/childhood lung to mucoinflammatory respons-
es thought to be triggered by viral infections and/or aspiration 
(1–3). Consistent with this notion, in the absence of recognizable 
bacterial infection, the bronchoalveolar lavage (BAL) of young 
children with CF contains mucus flakes containing both MUC5B 
and MUC5AC mucins accompanied by neutrophilic inflammation 
associated with increased IL-1α and IL-1β concentrations (3, 4). 
Subsequently, CF lung disease is worsened by bacterial infection 
superimposed on this mucoinflammatory state (5, 6). Aggressive 
bacterial eradication fails to prevent developing bronchiectasis 
in CF children and ferrets (7–9), suggesting that chronic mucoin-
flammation is a critical factor resulting in structural damage. The 
pathways/interactions that trigger persistent mucoinflammatory 
responses in the absence or presence of bacterial infection in the 
CF lung remain unclear.
Previous studies utilized CF airway secretions to identify the 
mechanisms of CF airway mucoinflammatory responses/disease 
(10–12). One recent study showed that supernatants of airway 
mucopurulent secretions (SAMS) administration to CF human 
bronchial epithelial (HBE) cell cultures increased both MUC5B 
and MUC5AC secretion without increase in ion/fluid secretion, 
producing abnormal mucus hyperconcentration (13). An unre-
solved question is the nature of the stimuli in SAMS that pro-
duced this combined MUC5AC/MUC5B response, i.e., bacterial 
versus host factors. IL-1β and IL-1α are found in SAMS (13), BAL 
from CF infants (12), and neonatal Scnn1b-Tg mice (14), a model 
of CF mucoobstructive lung disease (15). These data, plus previous 
reports of the beneficial effects of reducing IL-1α and IL-1β activi-
ty on mucus obstruction in Scnn1b-Tg mice (14), suggest that IL-1β 
and IL-1α may be key mucin secretagogues in CF airway secre-
tions. However, some in vitro studies reported that IL-1β induced 
MUC5AC but not MUC5B mRNA in primary HBE cells (16, 17), 
whereas other studies reported upregulation of MUC5B by IL-1β 
(18). Thus, the regulation of MUC5B mRNA levels by IL-1β relevant 
to increased MUC5B levels in CF airway secretions is unresolved.
IL-1β and IL-1α exert their activities through the IL-1 recep-
tor, type I (IL-1R1) (19). A natural inhibitor of IL-1R1 (IL-1 receptor 
antagonist [IL-1Ra]) exists that modulates a variety of IL-1R1–related 
immune and inflammatory responses (20). Several potential 
downstream pathways may link IL-1R1 signaling to mucin hyper-
secretion in CF. One candidate is SAM-pointed domain containing 
ETS transcription factor (SPDEF), a transcription factor (TF) that 
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higher in concentration compared with IL-1α (41.9 ± 5.5 vs. 1.1 ± 
0.5 ng/ml, P < 0.0001, mean ± SEM) (Figure 1B).
To determine whether IL-1α and IL-1β were the major mucin 
secretagogues in SAMS, a lentivirus vector expressing IL-1R1 gRNA 
and Cas9 (Supplemental Figure 2, A–C) was utilized to delete 
IL-1R1 in HBE cells. IL-1R1 CRISPR-modified HBE cells exhibited 
decreased MUC5B and MUC5AC mRNA expression in cells treat-
ed with PBS (baseline) compared with the control cells infected 
with lentivirus expressing EGFP gRNA/Cas9 (Figure 1C). Impor-
tantly, MUC5B and MUC5AC mRNA responses to SAMS exposure 
were markedly inhibited in IL-1R1 CRISPR-modified HBE cells 
(MUC5B decreased by 61% ± 21%, P = 0.013 and MUC5AC by 58% 
± 31%, P = 0.018; mean ± SD; Figure 1C). Notably, in response to 
SAMS, the IL-1R1 CRISPR also suppressed mRNA expression of 
SPDEF and epithelial derived proinflammatory mediators (IL8, 
Figure 1C; IL6 and CXCL1, Supplemental Figure 2D).
We next compared the histological changes in HBE cell cultures 
induced by IL-1α, IL-1β, SAMS, and IL-13. IL-1α, and IL-1β (both at 
10 ng/ml concentration in basolateral media) induced complex 
mucous cell metaplasia with an intraepithelial mucus accumula-
tion associated with MUC5B and MUC5AC apical hypersecretion, 
which was similar to findings associated with induction by SAMS 
(Figure 1D). Induction of mucin genes was similar with apical versus 
basolateral IL-1β exposure (Supplemental Figure 3A). In contrast to 
IL-1α, IL-1β and SAMS, IL-13 promoted classic goblet cell differ-
entiation and MUC5AC, but not MUC5B, intracellular expression 
(Figure 1D). IL-1α and IL-1β induced MUC5B and MUC5AC protein 
secretion from HBE cells as detected by Western blot followed by 
densitometry semiquantification, while IL-13 did not significantly 
change the secretion of either mucin after a 7-day exposure (Supple-
mental Figure 3, B and C).
Interestingly, at low concentrations (0.1 ng/ml), IL-1β induced 
classic goblet cell morphological changes, with both MUC5AC and 
MUC5B proteins present in mucin granules (Figure 2A). A higher 
concentration of 1 ng/ml IL-1β resulted in a shift in morphology 
with intraepithelial accumulation of mucus (Figure 2A). mRNA 
expression of MUC5B and MUC5AC was also IL-1β concentra-
tion dependent (R2 = 0.655, P < 0.0001 vs. R2 = 0.198, P = 0.022, 
respectively) in the 0 to 1 ng/ml range (Figure 2, B and C). No sig-
nificant differences in induction of MUC5B and MUC5AC mRNA 
were noted between 1 ng/ml and 10 ng/ml of IL-1β concentration 
(Supplemental Figure 3D).
Chronic IL-1β exposure leads to MUC5B-dominant mucin secre-
tion. We next compared IL-1β versus IL-13 in regulation of mucin 
mRNA and protein expression utilizing a chronic exposure (5 
week) protocol. IL-1β and IL-13 both induced formation of a 
thick apical mucus layer after 5 weeks (Figure 3A). Alcian blue– 
periodic acid Schiff–positive (AB-PAS–positive) glycoconjugates 
and histologically evident intraepithelial mucus accumulation 
were observed in IL-1β–treated cells. Classic goblet cells filled with 
AB-PAS–positive material were evident in IL-13–treated cultures 
(Figure 3C). Under these conditions, IL-1β promoted synthesis 
and secretion of a MUC5B-dominant mucus, whereas IL-13 pro-
duced a MUC5AC-dominant mucus (Figure 3, B, D, and E).
IL-1β increases mucus concentrations on CF HBE cell surfaces. 
Previous studies reported that SAMS exposure increased the 
concentration of apical mucus of CF, but not non-CF, HBE cells 
regulates mucous cell differentiation and mucin production in 
health (21) and disease (22–24). A second candidate is endoplas-
mic reticulum to nucleus signaling 2 (ERN2), a transmembrane 
ER stress sensor. Like Spdef, Ern2 is expressed in mucin secretory 
cells and is required for baseline and TH2 inflammation–induced 
mucin production in the mouse airways (23–25). Increased mRNA 
levels of SPDEF and ERN2 are associated with activation of unfold-
ed protein response (UPR) and increased MUC5B mRNAs in the 
distal airway epithelia in idiopathic pulmonary fibrosis (IPF) lungs 
(24). However, the roles of IL-1R1, SPDEF, and ERN2 in IL-1R1–
mediated regulation of both MUC5B and MUC5AC expression in 
mucoobstructive inflammatory diseases such as CF are unknown.
In the current study, we first investigated whether IL-1α and/
or IL-1β activates both MUC5B and MUC5AC secretion in HBE 
cells, producing a MUC5B-dominated mucus after chronic expo-
sure. Second, we used CRISPR/Cas9 technologies to determine 
whether the IL-1α and/or IL-1β in SAMS are the major transcrip-
tional regulators of both mucins and whether IL-1β is sufficient 
to raise CF airway mucus concentration. Third, we investigated 
whether IL-1α and/or IL-1β signaling can induce mucin expres-
sion and secretion in vivo and whether these effects are mediated 
by IL-1R1 and SPDEF. Fourth, we tested for upregulation of IL1B 
and MUC5B/MUC5AC mRNAs expression in excised CF lung 
distal airways using RNAscope and morphometry. Finally, we 
investigated IL-1R1 as a potential therapeutic target to disrupt the 
positive mucoinflammatory cycle centered on IL-1α and/or IL-1β 
signaling. A combination of primary human epithelial culture, in 
vivo mouse models, and freshly excised human lung tissues were 
employed to investigate these questions.
Results
Relative effectiveness of SAMS components in regulation of mucin 
gene expression. We first screened the major inflammatory cyto-
kines and interferons found in SAMS (13), including the TH17- and 
TH2-skewed cytokines reported in CF lungs (26), for MUC5B and 
MUC5AC mRNA regulatory activities (Supplemental Figure 1; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI125669DS1). In these studies, non-CF HBE 
cells were exposed to 12 different recombinant human inflam-
matory mediators for 3 days, and their regulation of mucin gene 
expression was compared with SAMS. SAMS raised both MUC5AC 
and MUC5B mRNA levels. IL-1α, IL-1β, TNF-α, IL-17A, and IL-13 
also raised MUC5AC mRNA expression. IL-1β and IL-1α induced 
the greatest fold change of MUC5B mRNAs (71 ± 16, P < 0.001 and 
40 ± 11, P = 0.031 respectively, mean ± SEM; Supplemental Table 
1), followed by IL-17F, TNF-α, IL-17A, and IFN-β. In contrast, IL-13 
and IFN-γ suppressed MUC5B mRNA expression. These studies 
led us to focus our attention on IL-1 signaling as a major regulator 
of both MUC5B and MUC5AC production.
Exposure of HBE cells isolated from 14 independent non-CF 
donors to IL-1α, IL-1β, or SAMS for 5 days produced increased 
MUC5B and MUC5AC mRNAs (Figure 1A). IL-13 (included as a 
control because its responses in HBE cells were well character-
ized) induced MUC5AC but inhibited MUC5B mRNAs, consistent 
with previous studies (27, 28). Because IL-1α and IL-1β were the 
most active cytokines in stimulating mucin secretions, their abso-
lute concentrations in SAMS were measured by ELISA. IL-1β was 
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Figure 1. Mucin secretagogue activity of SAMS is mediated by IL-1α and/or IL-1β via IL-1R1. (A) Expression of MUC5B and MUC5AC mRNAs in non-CF HBE 
cells as determined by TaqMan assays after exposure to control (PBS), IL-1α, IL-1β, IL-13, or SAMS of CF lung for 5 days. IL-1α, IL-1β, and IL-13 were adminis-
tered at 10 ng/ml in ALI media from basolateral side of the cells. Undiluted SAMS (50 μl) was administered to the apical surface of HBE cells, where it was 
maintained until the cells were utilized for assays. Scatter plots present mean ± SEM, with 1 culture of HBE cells obtained from 14 non-CF donors for each 
treatment condition. Data were analyzed with 1-way ANOVA followed by Dunnett’s test. (B) IL-1α and IL-1β protein concentration in SAMS was determined 
by ELISA. SAMS was collected from 8 CF lungs. Scatter plot presents mean ± SEM. (C) Non-CF HBE cells were infected with lentiviruses expressing EGFP 
(control) or IL-1R1 CRISPR guide RNA and Cas9 protein. After ALI was cultured for 4 weeks, CRISPR/Cas9 targeted cells were treated with vehicle control 
(PBS) or SAMS for 3 days. MUC5B, MUC5AC, SPDEF, and IL8 mRNAs in HBE cells were quantitatively measured by TaqMan assays. Scatter plots pres-
ent mean ± SD. Data were derived from HBE cells from n = 6 non-CF donors analyzed with 2-tailed paired t test. *P < 0.05; **P < 0.01; ***P < 0.001. (D) 
Histological changes of HBE cells after cytokine treatment are shown by H&E staining. Goblet cell differentiation and mucus production are shown by 
AB-PAS staining. Expression of MUC5B and MUC5AC protein is demonstrated by immunohistochemical staining. Micrographs present non-CF HBE cells of 
3 donors. Ψ, mucus layer; *, epithelial cell layer. Scale bar: 20 μm.
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expanded by CRC medium or the traditional bronchial epitheli-
al cell growth medium (BEGM) (Supplemental Figure 5A). Thus, 
the CF HBE cells failed to mount a Cl–/fluid secretory response to 
hydrate newly secreted mucins after IL-1β stimulation (16).
Next, we evaluated the effects of IL-1β, SAMS, and IL-13 on 
mRNA levels for CFTR and ANO1 (TMEM16A), whose fluid secre-
tory functions would be predicted to govern mucus concentra-
tions (32). Although there was considerable variability in respons-
es among human samples, 1-week exposure to IL-1β and SAMS 
moderately but significantly induced CFTR mRNA, while IL-13 
marginally increased CFTR mRNA, in both non-CF and CF HBE 
cells (Supplemental Figure 5B). In contrast, TMEM16A mRNA was 
induced by IL-13, but not by IL-1β or SAMS, in both non-CF and CF 
HBE cells (Supplemental Figure 5C).
IL-1α and IL-1β induce mucin gene expression and secretion in vivo. 
To determine whether human in vitro culture findings exhibit rel-
evance to in vivo conditions, wild-type (WT) adult C57BL/6J mice 
were exposed via intratracheal instillation to SAMS or purified 
recombinant murine cytokines IL-1α, IL-1β, and IL-13. SAMS and 
all 3 cytokines induced goblet cell metaplasia and increased Muc5b 
and Muc5ac protein and mRNA expression in the epithelia lining 
the conducting airways (Figure 5A). Consistent with these findings, 
Muc5b and Muc5ac protein secretion in BAL were increased in the 
(13). To determine whether IL-1β administration recapitulat-
ed this response, we evaluated epithelial morphology, MUC5B 
and MUC5AC protein and mRNA levels, and mucus wet-to-dry 
weight ratios (% solids, a measurement of mucus concentration) 
after a 1-week exposure to IL-1β versus IL-13. IL-1β produced 
intraepithelial and extracellular AB-PAS positive material, and 
IL-13 produced the classic goblet cell morphology in CF HBE cells 
(Supplemental Figure 4A). In the conditionally reprogrammed 
cell (CRC) culture conditions (29–31) used here, baseline MUC5B 
and MUC5AC mRNAs and secreted protein and mucus percent-
age of solids were not different between CF and non-CF HBE 
cell cultures (Figure 4, A–C, and Supplemental Figure 4, B and 
C). In both non-CF and CF HBE cells, secreted MUC5B and 
MUC5AC protein and mRNA levels were significantly increased 
by IL-1β, mimicking the effect of SAMS (Figure 4, A and B, Sup-
plemental Figure 4, B and C, and ref. 13). In contrast, IL-13 selec-
tively induced MUC5AC protein secretion in CF cells, and IL-13 
increased MUC5AC mRNA, but inhibited MUC5B mRNAs in 
both non-CF and CF cells (Figure 4, A and B, and Supplemental 
Figure 4, B and C). Notably, CF HBE cells, but not non-CF HBE 
cells, produced significantly higher apical mucus concentrations 
(percentage of solids) after IL-1β exposure compared with vehicle 
control (Figure 4C) regardless of whether the cells were initially 
Figure 2. IL-1β induces goblet cell differentiation and MUC5B expression in a concentration-dependent manner. Non-CF HBE cells were treated with IL-1β 
at a gradient of concentrations of 0.1, 0.3, 0.5, and 1 ng/ml from the basolateral side for 5 days. (A) Histological changes are shown by H&E staining and 
goblet cell differentiation by AB-PAS staining for treatment groups of 0, 0.1, and 1 ng/ml of IL-1β. Expression of MUC5AC/MUC5B protein was identified by 
immunohistochemical staining. Micrographs are representative of HBE cells from n = 3 donors in each treatment group. Scale bar: 20 μm. (B and C) Linear 
regression plots show correlations between mRNA expression of MUC5B or MUC5AC and IL-1β concentration (non-CF HBE cells; n = 9 donors).
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IL-1R1 is required for IL-1β–induced mucin and SPDEF expres-
sion in vivo. To test whether Il1r1 is required for IL-1β–induced 
mucin gene expression in vivo, Il1r1-deficient (Il1r1–/–) and WT 
(Il1r1+/+) mice were exposed via intratracheal instillation to 
recombinant murine IL-1β cytokine. Muc5b and Muc5ac mRNA 
expression in response to IL-1β were blunted in the lungs of 
Il1r1–/– mice (Figure 6A). Spdef mRNA, which was increased after 
IL-1β administration in WT mice, was also inhibited after both 
saline and IL-1β exposure in Il1r1-deficient mice (Figure 6A). 
Induction of Muc5b, Muc5ac, and Spdef mRNAs by IL-1α and 
IL-1β cytokine exposure was also suppressed in fully differentiat-
ed Il1r1–/– mouse tracheal epithelial cells (mTEC) (Figure 6B). In 
contrast, IL-13 induction of Muc5ac and Spdef mRNAs expression 
were preserved in Il1r1–/– mTECs (Figure 6B). Notably, in contrast 
to HBE cells, Muc5b was not downregulated by IL-13 in WT or 
mice administered with all 3 cytokines (Figure 5B), and mucin 
mRNAs were increased by all treatments in the whole-lung homog-
enates (Figure 5, C and D). All 3 cytokine treatments also induced 
expression of the goblet cell marker Clca1 (Gob5) (Supplemental 
Figure 6A), consistent with the histological findings.
Thus, except for the finding that Muc5b mRNA and protein 
were increased in IL-13–treated mice, the murine in vivo studies 
essentially replicated the in vitro results of HBE cells. To explore 
the discrepant IL-13 responses of Muc5b expression in mice in 
vivo, we evaluated the expression of pulmonary cytokines after 
IL-13 and IL-1α and/or IL-1 β administration. Interestingly, IL-13 
cytokine exposure induced endogenous Il1a and Il1b mRNAs, 
and IL-1α and L-1β exposure induced endogenous Il1b and Il17a 
mRNAs in the whole lung (Supplemental Figure 6B), providing the 
mechanisms for Muc5b upregulation in mice in vivo.
Figure 3. Chronic IL-1β exposure induces MUC5B-dominated mucin production. Non-CF HBE cells were exposed to vehicle control (PBS), IL-1β, or IL-13 
(10 ng/ml, from basolateral side in media) for 5 weeks without washing off the apical secretions. (A) Morphology of mucus layers, epithelial cell layers, 
and goblet cell differentiation are shown by H&E and AB-PAS staining. Ψ, mucus layer; *, epithelial cell layer. (B) Expression of MUC5B and MUC5AC in 
HBE cells after chronic IL-1β and IL-13 exposure was determined by dual-immunofluorescent staining. (C) High-power view of mucus layers, epithelial 
cell layers, and goblet cell differentiation showed in A. All micrographs are representatives of HBE cells from n = 3 donors in each treatment group. (D) 
Apical secretions of HBE cells after 5-week chronic exposure were subjected to trypsin digestion and analyzed with liquid chromatography–tandem mass 
spectrometry. MUC5B and MUC5AC proteins were identified and their quantities shown by total precursor intensities. HBE cells tested in control, IL-1β, 
and IL-13 exposure were collected from n = 8, 4, and 8 non-CF donor lungs, respectively. Scatter plots present mean ± SD. (E) mRNA expression of MUC5B 
and MUC5AC was measured by TaqMan assays in the HBE cells exposed to control (PBS), IL-1β, and IL-13 for 5 weeks. Data are represented as mean ± SEM. 
Non-CF HBE cells from n = 8 donor lungs were tested in each treatment group. Data were analyzed with 1-way ANOVA followed by Tukey’s test (D and E). 
*P < 0.05; **P < 0.01; ***P < 0.001, compared with control groups. Scale bars: 100 μm (A and B); 20 μm (C).
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IL-1R1–/– mTECs, as confirmed with multiple sets of probes (Fig-
ure 6B and Supplemental Figure 7A).
IL-1R1 CRISPR-modified HBE cells also exhibited decreased 
MUC5B, MUC5AC, and IL8 mRNAs at baseline and lost IL-1β 
induction of MUC5B, MUC5AC, SPDEF, IL8, IL6, and CXCL1 
mRNAs in comparison with EGFP (control) CRISPR-targeted cells 
(Figure 6C and Supplemental Figure 7B).
Spdef mediates IL-1β–induced mucin production. To gain further 
insights into the IL-1β–induced signaling pathway, RNA-Seq was 
performed in normal HBE cells cultured with or without IL-1β for 
24 hours. SPDEF was one of the most increased TFs (Supplemen-
tal Figure 8A). In further studies, SPDEF mRNA was found to be 
induced by IL-1β and SAMS, although to a lesser extent compared 
with the well-known SPDEF inducer IL-13 (22), in both non-CF 
and CF HBE cells (Supplemental Figure 8, B and C).
We next evaluated whether SPDEF, paralleling its role in 
TH2-dominated inflammation (23, 33), is required for IL-1β–trig-
gered mucus production by airway epithelia in vivo. WT (Spdef+/+) 
and Spdef-deficient (Spdef–/–) mice were administered with saline 
or recombinant murine IL-1β cytokine via intratracheal instilla-
tion. IL-1β induced Muc5ac, Muc5b protein/mRNA, and Spdef 
mRNA in WT mice (Figure 7, A–E). Absence of Spdef reduced 
goblet cell differentiation and suppressed Muc5b and Muc5ac 
protein/mRNA expression/secretion in the BAL both at baseline 
and after IL-1β (Figure 7, A–F, and Supplemental Figure 9). Spdef- 
regulated, mucin-pathway genes Foxa3 and Agr2 mRNAs (23) 
were also decreased in Spdef-deficient mice (Figure 7F).
SPDEF induces ERN2 to regulate mucin gene expression in air-
way epithelial cells. The UPR gene ERN2 is selectively expressed 
in secretory epithelia lining the intestine and respiratory tracts. 
ERN2 functions overlap with those of Spdef (24, 25) to induce 
mucin gene expression, suggesting involvement in the same sig-
naling cascade. To delineate a possible SPDEF-ERN2 hierarchy in 
IL-1β–induced mucus production in vivo, RNAscope and TaqMan 
assays were performed to measure expression of Ern2 and a close-
ly related isoform, Ern1 (34), in Spdef-deficient vs. WT mice. In 
naive adult Spdef-deficient mice, Ern2, but not Ern1, mRNA was 
absent in submucosal glands (SMGs) and superficial epithelia lin-
ing the proximal intrapulmonary airways, where Spdef is normally 
expressed (Supplemental Figure 10). Ern2, but not Ern1, mRNA 
Figure 4. IL-1β, but not IL-13, increases mucus 
percentage of solids in the apical secretions of 
CF HBE cells. Fully differentiated non-CF and CF 
HBE cells were exposed to control (PBS), IL-1β, or 
IL-13 (10 ng/ml from basolateral side in media) 
for 1 week. (A) Apical secretions from non-CF and 
CF HBE cells were collected by washing the apical 
surface of HBE cells with PBS containing 10 mM 
DL-dithiothreitol (DTT) to remove mucus. Secreted 
MUC5B and MUC5AC proteins were identified by 
mucin agarose gel Western blot. HBE cells from n = 
5 non-CF donors and n = 5 CF donors were used for 
each treatment condition. (B) MUC5B and MUC5AC 
protein content shown in A was semiquantified 
with Licor Odyssey software. Scatter plots represent 
mean ± SD. Data were analyzed with 1-way ANOVA 
followed by Dunnett’s test. (C) The percentage of 
mucus solids content, an index of hydration of api-
cal secretions, was measured from HBE cells after 1 
week of treatment with control, IL-1β (cells from n = 
9 non-CF and n = 9 CF donors), or IL-13 (cells from  
n = 5 non-CF and n = 5 CF donors). Data were ana-
lyzed with 1-way ANOVA followed by Dunnett’s test.
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expression was also substantially reduced in airway epithelia of 
Spdef-deficient mice after saline (control) and IL-1β exposure 
(Figure 8, A and B). Consistent with the notion that Spdef regu-
lates the Ern2 cascade in vivo, overexpression of a FLAG-Spdef 
lentivirus in normal HBE cells (Supplemental Figure 11A) induced 
ERN2 mRNA, MUC5B, and MUC5AC mRNA/protein expression/
secretion and Spdef-regulated genes FOXA3 and AGR2, but not 
ERN1 mRNAs (Figure 8, C–E, and Supplemental Figure 11, B–D). 
Further, inhibition of SPDEF expression by transfection of SPDEF 
siRNA suppressed SPDEF, ERN2, MUC5B, and MUC5AC, but not 
ERN1 mRNAs expression, in an immortalized mucus-producing 
HBE cell line UNCN3T (ref. 35 and Figure 8F).
Figure 5. SAMS, IL-1α, IL-1β, and IL-13 induce goblet cell differentiation and mucus production in vivo. (A) WT adult (6 weeks) female C57BL/6J mice were 
exposed to sterile saline and murine recombinant IL-1α, IL-1β, IL-13, or SAMS via intratracheal instillation. Goblet cell differentiation and Muc5b and Muc5ac 
protein/mRNA expression in conducting airway epithelia were identified by AB-PAS and immunohistochemical staining and RNAscope (Muc5ac/Muc5b) 
duplex assays. Inserts show high-power view of airway epithelia. Micrographs are representatives of lung histology of n = 3 mice/treatment group. Micro-
graphs of AB-PAS, Muc5ac, and Muc5b immunohistochemical staining were taken at the same magnification. Scale bars: 200 μm (top three rows); 20 μm 
(bottom row). Original magnification, ×40 (insets). (B) Secreted Muc5b and Muc5ac proteins in BAL were examined by mucin agarose gel Western blot  
(n = 4 mice/treatment group). (C) mRNA expression of Muc5b and Muc5ac in the whole lung was quantitatively measured by TaqMan assays after saline, 
IL-1α, IL-1β, and IL-13 (n = 5 mice/treatment group). (D) Muc5b and Muc5ac mRNAs in the whole lung were quantitatively measured in mice exposed to 
saline and SAMS (n = 6 mice/group). Scatter plots present data as mean ± SD; data were analyzed with 1-way ANOVA followed by Dunnett’s test (C) and 
2-tailed, unpaired t test (D). *P < 0.05; **P < 0.01; ***P < 0.001, compared with saline groups.
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detected in the cells trapped in the airway lumen (Figure 9B and 
Supplemental Figure 12). SPDEF signals were detected throughout 
the airway, but at increased levels in CF compared with non-CF 
(Figure 9C). ERN2 mRNA expression was also greatly increased 
in CF compared with non-CF in proximal and distal airway epi-
thelia (Figure 9D). The MUC5B and MUC5AC mRNA expression 
patterns overlapped with those of SPDEF and ERN2 in CF lungs, 
supporting roles for SPDEF and ERN2 in mediating IL-1β–induced 
mucin gene expression.
The overall visual expression patterns observed for these genes 
were confirmed by both morphometric (focusing on distal airways) 
and quantitative reverse-transcriptase PCR (RT-PCR) analyses. 
First, morphometric analyses were performed to quantitate the 
expression of MUC5B/MUC5AC and IL1B/IL1A mRNAs in CF 
versus non-CF distal airways (luminal diameter ≤1.5mm) (Sup-
plemental Figure 12). MUC5B mRNA expression was significantly 
higher (P = 0.020), and MUC5AC mRNA showed a trend toward 
higher expression (P = 0.062) in the distal airway epithelia of CF 
versus non-CF subjects (Figure 10A). IL1B mRNA expression was 
Expression of IL1B, SPDEF, and ERN2 mRNAs is associated with 
mucin gene expression in CF lung tissue. RNAscope assays were per-
formed to localize mRNA expression of MUC5AC/MUC5B, IL-1B/
IL1A, SPDEF, and ERN1/ERN2 in proximal bronchi transitioning 
to terminal bronchioles (Figure 9, A–D) in non-CF and CF lungs. 
MUC5B mRNA was detected in proximal airway superficial epithe-
lium of non-CF lungs, with a gradual reduction of expression in dis-
tal-to-terminal airways (Figure 9A). In the CF lungs, MUC5B mRNA 
expression was greater in the distal airways than in non-CF lungs, 
and MUC5B mRNA was also detected in the terminal airways. 
MUC5AC mRNA was weakly expressed in proximal airways of non-
CF lungs, but strongly expressed in proximal bronchi in CF lungs. In 
distal-to-terminal airways, MUC5AC mRNA was rarely detected in 
control subjects, but readily detectable in CF airways (Figure 9A).
Neither IL1B nor IL1A mRNA was readily detected in non-
CF lungs (Figure 9B). In CF lungs, IL1B mRNA was observed in 
the cells trapped in luminal mucus plugs and occasionally in the 
cells present in the airway epithelia (Figure 9B). IL1A mRNA was 
weakly detected in CF cells in the epithelial layer and sporadically 
Figure 6. Loss of IL-1R1 inhibits IL-1β–induced mucin and SPDEF gene expression. (A) WT (Il1r1+/+) and Il1r1-deficient (Il1r1–/–) mice were exposed to sterile 
saline or murine recombinant IL-1β cytokine via intratracheal instillation, and mRNA expression of Muc5b, Muc5ac, and Spdef in the whole lung was quanti-
tatively determined by TaqMan assays. n = 3–5 mice/treatment/genotype. (B) mTECs isolated from WT and Il1r1–/– mice were cultured under air-liquid inter-
face conditions for 3 weeks to allow full differentiation prior to exposure with vehicle control (PBS) or murine recombinant cytokines IL-1α, IL-1β, and IL-13 for 
1 week from basolateral media (all at 10 ng/ml). mRNA expression of Muc5b, Muc5ac, and Spdef was quantitatively measured by TaqMan assays with n = 3 
independent mTEC cultures/treatment/genotype. Scatter plots in A and B present data as mean ± SD, and data were analyzed with 2-tailed unpaired t test. 
(C) Non-CF HBE cells were infected with lentiviruses expressing EGFP (control CRISPR) and IL-1R1-CRISPR guide RNAs and Cas9 protein. After culturing at 
air-liquid interface for 4 weeks, CRISPR/Cas9 targeted cells were treated with vehicle control (PBS) or IL-1β for 3 days. MUC5B, MUC5AC, and SPDEF mRNAs 
in HBE cells were quantitatively measured by TaqMan assays. Scatter plots present data as mean ± SD, and data were analyzed with 2-tailed paired t test 
with HBE cells from n = 3 donor lungs. *P < 0.05; **P < 0.01; ***P < 0.001, compared with Il1r1+/+ groups (A and B) or EGFP CRISPR groups (C).
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were associated with increased MUC5B and MUC5AC mRNAs 
expression in CF airway cells (Supplemental Figure 13, B–D).
IL-1R antagonist suppresses expression of SAMS-induced mucins 
and proinflammatory mediators. Administration of IL-1Ra concur-
rently to both apical and basolateral surfaces of HBE cells inhibit-
ed SAMS-induced MUC5B and MUC5AC mucin gene expression 
(Figure 11, A and B). This effect was associated with inhibition 
of SPDEF and the mucin chaperone protein AGR2 (36) mRNA 
expression in both non-CF and CF HBE cells (Figure 11, C and D). 
IL-1Ra inhibited SAMS-induced ERN2 upregulation in non-CF, 
but not CF, HBE cells (Figure 11E). These data suggest the pres-
ence of other pathways that may regulate ERN2 mRNA expression 
in CF epithelia. Gene expression of proinflammatory mediators, 
higher (P = 0.014) in the cells trapped in the distal airway lumens, 
with a trend toward higher expression (P = 0.062), in the distal 
airway epithelia, in CF versus non-CF subjects. In contrast, IL-1A 
mRNA was not significantly different between CF and non-CF 
subjects in either compartment (Figure 10, B and C). Consistent 
with RNAscope data, quantitative RT-PCR conducted on mRNAs 
from airway epithelial cells freshly isolated from CF compared with 
non-CF/nonsmoker donors demonstrated increases in SPDEF, 
ERN2, MUC5B, and MUC5AC mRNAs in CF compared with non-
CF subjects (Figure 10D). Further, SPDEF-regulated genes FOXA3 
mRNAs (23) were also increased in CF versus non-CF freshly iso-
lated HBE cells (Supplemental Figure 13A). Importantly, SPDEF 
mRNA expression correlated with ERN2 mRNA levels, and both 
Figure 7. Spdef is required for 
IL-1β–induced goblet cell differen-
tiation and mucin production in 
vivo. WT (Spdef+/+) and Spdef- 
deficient (Spdef–/–) 6-week-old mice 
were exposed to sterile saline or 
murine recombinant IL-1β cytokine 
via intratracheal instillation. 
Goblet cell differentiation was 
examined by AB-PAS staining (A), 
and Muc5ac and Muc5b protein/
mRNA expression in the conducting 
airway epithelia was assessed by 
immunohistochemical staining (B 
and C) and RNAscope duplex assays 
(D). (E) Spdef mRNA expression in 
the conducting airway epithelia was 
identified by RNAscope red assays. 
(A–E) Micrographs are represen-
tative of n = 3 mice/treatment/
genotype. Scale bars: 100 μm (A–D); 
20 μm (E). (F) mRNA expression of 
Muc5ac, Muc5b, Foxa3, and Agr2 
from the whole lung was quantita-
tively measured by TaqMan assays. 
In the Spdef+/+ mouse group, n = 5 
and n = 6 mice were treated with 
saline and IL-1β, respectively. In the 
Spdef–/– mouse group, n = 5 and  
n = 7 mice were treated with saline 
and IL-1β, respectively. Scatter plots 
present data as mean ± SD, and 
data were analyzed with 2-tailed 
unpaired t test. *P < 0.05; **P < 
0.01; ***P < 0.001, compared with 
saline groups.
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mucus/epithelial hypoxia (39). It appears likely that the next stage 
of disease reflects infection of hypoxic mucus by anaerobic bacteria 
aspirated from the oral cavity into the lung (6, 40). Subsequently, 
there is acquisition of classic CF bacterial pathogens, e.g., Staphylo-
coccus and Pseudomonas. Acquisition of these bacteria is associated 
with an acceleration of the rate of loss of lung function (41). There 
are multiple aspects of this paradigm that remain unclear. First, 
the pathogenesis of CF airway mucus stasis/obstruction has been 
assigned to either raised mucus concentrations or reduced pH (42–
44). Second, the site of initial abnormal mucus production, i.e., large 
airway SMGs versus small airway superficial epithelia, is debated (3, 
45). Finally, it is unclear how a “vicious” mucoinflammatory cycle 
that perpetuates and accelerates CF lung disease is initiated.
e.g., IL8, IL6, and CXCL1, and innate host defense molecules, e.g., 
β-defensin 2 (DEFB4B) and lactotransferrin (LTF) (37), was also 
decreased by recombinant IL-1Ra at baseline and/or after SAMS 
administration in non-CF and CF HBE cells (Figure 11, F–H, and 
Supplemental Figure 14).
Discussion
CF presents as a progressive respiratory disease characterized by 
airway mucus obstruction, chronic neutrophilic inflammation- 
associated airway destruction, i.e., bronchiectasis, and bacterial 
infection (38). Neonatal/early CF childhood lung disease is charac-
terized by a bacterially sterile, mucoinflammatory state that includes 
adhesion of mucus plaques/plugs to airway surfaces with local 
Figure 8. SPDEF regulates ERN2 and mucin production in vivo and in vitro. (A) WT (Spdef+/+) and Spdef-deficient (Spdef–/–) 6-week-old mice were 
exposed to sterile saline or murine recombinant IL-1β via intratracheal instillation. Ern2 mRNA in conducting airways was detected by RNAscope assay. 
Micrographs are representative of n = 3 mice/treatment/genotype. Arrows point to regions shown in inserts. (B) Ern2 and Ern1 mRNAs in whole lung were 
quantitatively measured by TaqMan assays. The scatter plots present data as mean ± SD; data were analyzed with 2-tailed unpaired t test. For Spdef+/+ 
mice, n = 5 and n = 6 mice were administered saline and IL-1β, respectively. For Spdef–/– mice, n = 5 and n = 7 mice were administered saline and IL-1β, 
respectively. (C) Non-CF HBE cells were infected with lentiviruses expressing GFP (control) or FLAG-Spdef fusion protein and cultured under ALI conditions 
for 1 week. Goblet cell differentiation and MUC5B/MUC5AC protein expression were revealed by AB-PAS and dual-immunofluorescent staining, respective-
ly. (D) MUC5B and MUC5AC mRNA levels were quantitatively measured in GFP vs FLAG-Spdef–transduced cultures by TaqMan assays. ERN1/ERN2 mRNA 
expression was identified by RNAscope duplex assay and quantitatively determined by TaqMan assay (C and E). Data were analyzed with 2-way ANOVA 
followed by Šidák’s correction. Non-CF HBE cells from n = 5 donors (n = 3 independent cultures/donor) were used for lentiviruses infection, and the same 
donor cells infected with GFP or FLAG-Spdef viruses were labeled with color-matching dots. (F) Immortalized HBE cells (UNCN3T) were transfected with 
negative control or SPDEF-specific siRNA, and SPDEF, ERN1, ERN2, MUC5B, and MUC5AC mRNAs were quantitatively measured after 48 hours. Scatter 
plots present data as mean ± SD with n = 4 independent cell cultures, and data were analyzed by 2-tailed, unpaired t test. *P < 0.05; **P < 0.01; ***P < 
0.001, compared with saline (B), GFP (D and E), and control siRNA (F) groups. Scale bars: 50 μm (A); 20 μm (C). Original magnification, ×60 (insets).
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Figure 9. Expression of IL1B, SPDEF, and ERN2 mRNAs is associated with MUC5B mRNA in proximal to terminal airway epithelia in CF. Expression 
of MUC5AC, MUC5B, IL1B, IL1A, SPDEF, ERN1, and ERN2 mRNAs was detected by RNA in situ hybridization in non-CF (control) and CF lung subjects. 
The representative histological sections contain airways ranging from the proximal (bronchial) airways (the regions containing SMG; the airway luminal 
diameter is around 5 mm) to intermediate (2–4 mm) and distal (1–2 mm), and further to terminal regions (≤200 μm) in each panel. Detection of expres-
sion of these genes was performed on the matched sequential sections for each assay. MUC5AC/MUC5B (A) and IL1B/IL1A (B) mRNAs were detected by 
RNAscope duplex assays. (C) Detection of SPDEF mRNA expression by Basescope assays. (D) ERN1/ERN2 mRNA expression was detected by RNAscope 
duplex assays. In B, the inserts at bottom left corners show high-power view of the selected areas of airway tissue from both non-CF and CF subjects, and 
the inserts at the upper right corners show high-power views of the selected area containing the cells trapped in the luminal mucus plugs in CF lung tissue. 
In A, C, and D, inserts show high-power view of rectangle-selected areas on airway tissues. Micrographs are representative of RNAscope assays performed 
with n = 4 non-CF and n = 3 CF lungs. Scale bars: 200 μm. Original magnification, ×60 (insets).
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Figure 10. Quantification of MUC5B/
MUC5AC and IL1B/IL1A mRNA expression 
in the distal airways of control and CF 
lungs. (A) Quantification of the MUC5B/
MUC5AC mRNA signals in superficial 
epithelia lining of the distal airways 
(including all the airways with luminal 
diameter of 1.5 mm or less, regardless of 
staining status; shown in Figure 9) was 
determined by morphometric analysis of 
staining volume density. Quantification 
of the IL1B/IL1A mRNA signal content 
present in the luminal areas (B) and signal 
volume density in the epithelial layers 
(C) of the distal airways (same criteria as 
in A) was performed by morphometric 
analyses. Signal volume density in A and C 
was normalized to the unit surface area of 
the basement membrane (BM), while the 
luminal contents of IL1B/IL1A staining in B 
was normalized to the unit luminal volume 
(LV). Measurements of n = 4 control sub-
jects and n = 3 CF subjects were performed. 
Individual subjects are distinguished by 
color-matched dots (A–C). Each color dot 
represents measurement from 1 airway, 
and the numbers of the airways used in 
analyses from 1 subject were annotated as 
n = following the color dots in the figure 
annotations. Of note, the scatter dots/bar 
graphs represent cube root–transformed 
values. The differences of means between 
the 2 groups (denoted by P values) were 
analyzed by linear mixed-effects model 
with subject identification number as 
random intercept variable. (D) mRNA 
expression of SPDEF, ERN2, MUC5B, and 
MUC5AC was quantitatively measured by 
TaqMan assays (normalized to endogenous 
GAPDH mRNA) from the airway epithelial 
cells freshly isolated (passage 0) from 
nonsmoker, non-CF donors (control, n = 
30 codes) and CF donors (n = 24 codes). 
One code means the cells obtained from 1 
individual donor lung. Scatter plots present 
data as mean ± SEM, and data were ana-
lyzed with 2-tailed unpaired Mann- 
Whitney U test.
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in mucin secretion and airway surface liquid (ASL) volume (hydra-
tion), the latter via upregulated CFTR expression/function. The 
CFTR-mediated fluid secretory response effectively “flushes” 
mucus and trapped materials from the normal lung (51). In contrast, 
SAMS exposure to CF HBE cells was characterized by increased 
mucin secretion, but no CFTR-mediated fluid secretion. Hence, CF 
airway epithelia responded to SAMS to produce characteristic mucus 
hyperconcentration (13). Importantly, IL-1β, but not IL-13, mimicked 
the abnormal mucus hyperconcentration phenotype induced by 
SAMS in CF airway epithelia (Figure 4C and ref. 13). These differ-
ential responses likely reflect: (a) the coordination of IL-1α–induced 
and IL-1β–induced mucin secretion and CFTR-mediated fluid secre-
tion, the latter of which is absent in CF, versus (b) IL-13 regulation of 
ion channels that promote fluid secretion via the ion channel inde-
pendent of CFTR, e.g., SLC26A9 (52), and calcium-activated chlo-
ride channel TMEM16A (ref. 53 and Supplemental Figure 5C).
MUC5B is the dominant secreted airway mucin in health 
and indeed CF (54, 55), and our data suggest that the increase of 
Previous studies investigating elucidation of the signaling 
pathways that mediate the persistent mucoinflammatory cycle 
in CF airways have reported that multiple components of airway 
secretions stimulate CF airway mucin secretion and neutrophilic 
inflammation (11, 13, 46). Classic mucin secretagogues identified 
in SAMS include LPS, proteases, including neutrophil elastase, 
purine nucleotides, and a spectrum of cytokines, including IL-1α, 
IL-1β, TNF-α, and IL-17A/F, and neutrophilic cytokines/chemo-
kines, including IL-8 (13, 47, 48). It was perhaps surprising that our 
data indicated that there was a dominant factor in SAMS that regu-
lated both MUC5B and MUC5AC expression, i.e., IL-1α and IL-1β, 
acting through the IL-1R1 (Figure 1C and Figure 11). Quantitatively, 
IL-1β was found in higher concentrations than IL-1α in SAMS. IL-1β 
synthesis in the CF lung appears to be a feature of intraluminal 
macrophages and interstitial mononuclear cells (49, 50), whereas a 
component of epithelial release was identified for IL-1α (14).
We have previously reported that both SAMS (13) and IL-1β (16) 
administration to non-CF HBE cells produce coordinated increases 
Figure 11. IL-1Ra inhibits SAMS-in-
duced expression of mucin and 
proinflammatory genes in both non-
CF and CF HBE cells. Fully differen-
tiated non-CF and CF HBE cells were 
pretreated with vehicle (PBS) or IL-1 
receptor antagonist IL-1Ra (at 2 μg/
ml from the apical side and 400 ng/ml 
from the basolateral side) for 24 hours 
prior to exposure to diluted SAMS 
(1:40 dilution of stock SAMS with 
sterile PBS to reach 1 ng/ml of IL-1β 
concentration) in SAMS+IL-1Ra admin-
istration was compared with control 
treatment (PBS and IL-1Ra) for 3 days. 
mRNA expression of MUC5B (A), 
MUC5AC (B), SPDEF (C), AGR2 (D), and 
ERN2 (E) and proinflammatory medi-
ators IL8, IL6, and CXCL1 (F–H) were 
quantitatively measured by TaqMan 
assays. Graphs present data as mean 
± SD with n = 2 independent HBE cell 
cultures of non-CF (from n = 5 donor 
lungs) and CF (from n = 5 donor lungs). 
Data were analyzed using 2-way  
ANOVA followed by Tukey’s test.  
*P < 0.05; ***P < 0.001, compared 
with vehicle-treated groups.
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in modulating MUC5AC overexpres-
sion that characterizes the CF lung. 
These data include the following: (a) 
IL-1α and IL-1β induced MUC5AC 
expression to levels comparable to 
those with IL-13 (Figure 1, Figure 4, A 
and B, and Supplemental Figure 4C); 
(b) IL-1α and IL-1β produced the coor-
dinate upregulation of both MUC5AC 
and MUC5B mRNAs, consistent with 
RNAscope data from CF lungs (Fig-
ure 9A and Figure 10), whereas IL-13 
raised MUC5AC, but suppressed 
MUC5B mRNA levels in human air-
way epithelia; and (c) CRISPR/Cas9 
deletion of IL-1R1 or IL-1Ra admin-
istration markedly reduced stimula-
tion of MUC5AC expression by SAMS 
(Figure 1C and Figure 11).
The investigation of the role of 
TH2 cytokines in CF was complicated 
by the discrepancy in IL-13 regulation 
of mucin gene expression, particu-
larly MUC5B, between human and 
mouse models (58). In human HBE 
cells, IL-13 induced MUC5AC and 
inhibited MUC5B mRNAs, consistent 
with reports of increased MUC5AC 
and decreased MUC5B, protein, and 
mRNA in sputum (59) and bronchial 
epithelia (60) from severe/exacer-
bating asthma patients, respective-
ly. However, IL-13 induced Muc5ac 
without affecting Muc5b mRNAs 
in mTEC cultures (Supplemental 
Figure 7A). Further, IL-13 adminis-
tration to WT mice in vivo induced 
both Muc5b and Muc5ac protein and 
mRNAs (Figure 5). The in vivo effect 
of IL-13 on Muc5b levels could in part 
reflect IL-13–induced stimulation of 
Muc5b-active cytokines after intra-
tracheal instillation, e.g., increased 
endogenous IL-1α and IL-1β expres-
sion in the lung (Supplemental Figure 
6B). However, the absence of Muc5b 
suppression by IL-13 in mTEC in vitro 
suggests more basic differences in IL-13/MUC5B regulatory path-
ways in mouse versus human airway epithelia.
IL-1α and IL-1β have been reported to be elevated in BAL from 
children in the Australian Respiratory Early Surveillance Team for 
Cystic Fibrosis (AREST-CF) study (12), concurrent with elevated 
mucin levels, elevated neutrophil levels, and often the absence of 
bacterial infection (3, 8). The concept of persistent, sterile, mucoin-
flammation that emerged from the AREST-CF studies has been 
reinforced by studies of neonatal Scnn1b-Tg mice (airway-targeted 
overexpression of the epithelial Na+ channel β subunit) raised under 
MUC5B expression in airways of CF largely reflects IL-1α–medi-
ated and IL-1β–mediated regulation. However, MUC5AC is also 
upregulated in CF airway superficial airway epithelia (Figure 9A). 
MUC5AC upregulation in lung disease has typically been associ-
ated with TH2 cytokines, e.g., IL-13 (27). TH2 cytokines may play 
a role in CF mucoobstructive lung disease via an overlap “asth-
ma-CF” scenario, i.e., 40%–70% of CF subjects exhibit signs of 
asthma (56) and 10% of CF patients have features of allergic bron-
chopulmonary aspergillosis (ABPA) (57). Our data, however, sug-
gest a lesser role for TH2 signaling compared with IL-1α and IL-1β 
Figure 12. Positive feedback cycle between IL-1 cytokines/inflammation and mucus hyperconcentration in 
the CF airways. (A) CF babies are born with sterile lungs. At their basal state, the ASL hydration and mucus 
concentration may be relatively normal. (B) Insults, e.g., aspiration (bile acids), promote mucin secretion, 
and due to loss of CFTR function, which limits Cl–/water secretion into the ASL, the mucus becomes 
dehydrated. Dehydrated mucus activates local luminal macrophages and produces hypoxia in epithelia. (C) 
Hypoxia-induced necrotic epithelia secrete IL-1α (upper right and bottom left). In response to hyperconcen-
trated mucus or epithelial-released IL-1α, the luminal resident macrophages and myeloid cells in mucosa 
are then activated to release IL-1β (upper left and bottom left, respectively). Secreted IL-1α and IL-1β activate 
IL-1R1 on apical or basolateral side of the epithelia to (a) induce SPDEF and ERN2-mediated mucin tran-
scription and secretion and (b) increase expression of proinflammatory mediators, e.g., IL-8 and CXCL1. Prior 
to bacterial infection occurrence in CF infants/young children, the dehydrated secreted mucin exacerbates 
existing mucus hyperconcentration on CF airways that further activates the luminal macrophages leading 
to a “vicious” positive feedback cycle. Note, each step of this positive feedback cycle is denoted by a red 
cross. Secretion of proinflammatory mediators induces a parallel polymorphonuclear neutrophil–mediated 
inflammation, which persists in early CF lungs. Elastase secreted by neutrophils also activates mucin pro-
duction by CF epithelia, which further contributes to mucus hyperconcentration and obstruction in the distal 
airways, another positive feedback cycle (not shown). pO2, partial pressure of oxygen.
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cellular hypoxia; and (b) reducing IL-1α and/or IL-1β stimulation 
of neutrophilic inflammation, with its concomitant downstream 
promucin secretory activity (Figure 12 and refs. 46, 47).
Anakinra has been used for treatment of rheumatoid arthritis 
in humans and has a substantial record of safety. With respect to 
preclinical studies in CF-like lung disease, anakinra treatment did 
not aggravate acute P. aeruginosa (PAO1) infection in either WT or 
Scnn1b-Tg mice (68), supporting the concept that anakinra could 
serve as a therapeutic approach for resolving mucoinflammato-
ry obstruction, without worsening bacterial infection in CF lung. 
Nevertheless, anakinra treatment was recently found to produce 
increased susceptibility of infection with group A Streptococcus 
(69), a common CF pathogen, in human subjects. In part, this sus-
ceptibility may reflect the fact that IL-1Ra inhibits SAMS-induced 
antimicrobial and innate defense gene expression, e.g., β-defen-
sin and lactotransferrin, in HBE cells (Supplemental Figure 14). 
One interpretation of the risk-benefit aspects of anakinra suggests 
that this agent may have therapeutic benefits in CF subjects prior 
to occurrence of infection to suppress mucus obstruction, inflam-
mation, and lung structural damage during early childhood, but 
may not suitable for treatment of CF patients who exhibit chronic 
bacterial infections. Clinical data in CF patients will be required to 
resolve this issue.
There are several limitations to this current study. First, the 
role of IL-1 signaling in the SMGs could not be evaluated in our 
model. Previous reports have suggested that IL-1α and IL-1β are 
constitutively expressed in SMGs (70), where MUC5B is basally 
produced, and an important future question will be whether IL-1 
signaling plays a role in SMG hypertrophy in CF. Second, SAMS is 
complex, with multiple secretagogues, and the work reported here 
primarily investigated IL-1 signaling in isolation. Even though we 
show a major role for IL-1 signaling, clearly other mediators are 
present, which may contribute to, or interact with, IL-1α/IL-1β 
signaling. Future studies will be required to quantitate the relative 
effectiveness of IL-1α and IL-1β, as compared with other promucin 
stimulatory cytokines (e.g., IL-17A, TNF-α). Third, in our studies, 
a significant increase in mucus concentration of apical secretions 
was not observed between CF and non-CF HBE cells at baseline 
in our studies. We speculate that this result reflects a relative 
small difference in percentage of solids at baseline between CF 
and non-CF HBE cells under “noninsulted”, i.e., unstimulated 
conditions, and the variability of the mucus percentage of solids 
values/measurements in the HBE cells obtained from different 
donors. Importantly however, our results with IL-1β present mim-
ic the results in CF subjects, in whom CF sputum (produced in an 
inflammatory environment) exhibits consistently higher concen-
tration than sputum obtained from non-CF sputum (55).
In summary, IL-1α and IL-1β have been identified as the dom-
inant non-TH2 inflammatory cytokines in CF airway secretions 
that promote goblet cell differentiation, mucus secretion, and 
mucin hyperconcentration. IL-1α and IL-1β trigger these respons-
es to produce positive feedback cycles that maintain or worsen 
the CF airway mucoinflammatory state. IL-1Ra suppresses SAMS- 
induced mucin and proinflammatory gene expression, providing 
a rationale for use of IL-1Ra as a therapeutic option for treating 
mucus obstruction and neutrophilic inflammation–mediated air-
way structural damage in young CF children.
gnotobiotic conditions (61) and CFTR-knockout ferrets raised with 
broad-spectrum antibiotics (9). Our data suggest that this “vicious” 
cycle of mucin secretion and inflammation in the absence or pres-
ence of bacterial infection reflects parallel positive feedback cycles. 
This model positions IL-1α and IL-1β as signals that perpetuate the 
mucus hyperconcentration/obstruction resulting from CFTR defi-
ciency–induced ASL depletion (Figure 12).
One limb of the positive feedback cycle describes mucus 
obstruction–induced epithelial hypoxia and necrosis, with IL-1α 
release from necrotic epithelia (14). The released IL-1α stimulates 
mucin but not CFTR-mediated fluid secretion, worsening mucus 
hyperconcentration and stimulating increased IL-1α release. The 
second limb of the pathway focuses on intraluminal macrophages 
trapped in mucus plaques/plugs. Activation of these macro-
phages, likely by mucin concentration–dependent Siglec receptor 
activation and/or endogenous danger-signaling molecules (e.g., 
HMGB1) from necrotic epithelial cells (62, 63), stimulates secre-
tion of IL-1β in a NLRP3-inflammasome–dependent manner (49, 
64). The released IL-1β from luminal resident macrophages and 
mucosal myeloid cells (65) promotes mucin hypersecretion that, 
in the absence of CFTR-dependent fluid secretion, again worsens 
mucus hyperconcentration and obstruction, macrophage activa-
tion, and IL-β release rates. These positive-feedback loops can be 
amplified by the following: (a) chronic infection (bacterial, fungal, 
and viral) that increases both IL-1α and IL-1β release, as reported 
in BAL of CF children (12); and (b) IL-1α and IL-1β and hypoxic cell 
stimulation/release of neutrophil chemokines, neutrophil accu-
mulation, and release of neutrophil products, e.g., elastase, that 
may further stimulate mucin secretion (66).
Downstream signaling components of the IL-1 receptor, e.g., 
SPDEF and ERN2, were identified (Figure 11, C and E). Induction 
of SPDEF mRNA expression by SAMS or IL-1β (Supplemental Fig-
ure 8) provides an explanation for the role of SPDEF in non-TH2 
inflammatory pulmonary diseases (23, 24, 67). We also found 
that SPDEF regulated ERN2 (Figure 8 and Supplemental Figure 
10), suggesting that SPDEF regulates mucin production, at least 
in part, via the UPR pathway (24). Thus, both SPDEF and ERN2 
contribute to the positive feedback cycle connecting inflammatory 
mediators, e.g., IL-1α and IL-1β, to mucin secretion.
Blocking IL-1R1 activation by IL-1Ra (anakinra) has been tested 
for effects on neutrophilic inflammation and infection in CF mouse 
models (Cftr–/–) (64) and a mucoobstructive CF-like mouse model 
(Scnn1b-Tg) (14). Our finding that IL-1R1 was required for SAMS-, 
IL-1α–, and IL-1β–induced, but not IL-13–triggered, mucin produc-
tion by human and mouse airway epithelia (Figure 1C and Figures 6 
and 11) provides further proof of concept that IL-1Ra inhibition may 
be therapeutically beneficial for mucus hypersecretion in CF lungs. 
Notably, IL-1Ra blocked SAMS-induced mucin (MUC5AC, MUC5B) 
and proinflammatory mediator (IL8, IL6, and CXCL1) gene expres-
sion in non-CF and CF HBE cells (Figure 11). These effects of 
IL-1Ra in human airway epithelia are consistent with the reduced 
mucus obstruction and neutrophilic inflammation/KC expression 
in anakinra–treated Scnn1b-Tg mice and Cftr–/– mice exposed to 
Pseudomonas aeruginosa (14, 64). The cumulative data suggest that 
IL-1Ra may disrupt the positive feedback cycle described in Figure 
12 by the following: (a) blocking the IL-1α and/or IL-1β activation 
of IL-1R1, limiting mucin hypersecretion, hyperconcentration, and 
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significant. Data are presented as mean ± SD or SEM unless otherwise 
indicated in the figure legend.
Study approval. Four deidentified CF samples from lung trans-
plant explants and 4 control lung tissue samples from donors with no 
preexisting pulmonary diseases, fresh or frozen primary HBE cells 
from non-CF and CF donors that were used for in vitro culture and 
used for gene expression assays (immediately lysed after fresh iso-
lation from the airways for total RNA purification at passage 0), and 
UNCN3T cells (35) (at passage 11) were provided by the Tissue Pro-
curement and Cell Culture Core of Marsico Lung Institute University 
of North Carolina at Chapel Hill (ID 03-1396). Mice were maintained 
and studied under protocols approved by the University of North Car-
olina IACUC (ID: 15-249.0).
Further information is available in the Supplemental Methods.
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Methods
Mouse models. WT C57BL/6J and Il1r1–/– mice were purchased from 
the The Jackson Laboratory (stock no. 000664, 003245). Spdef−/− 
(C57BL/6N) mice were obtained from Jeffrey Whitsett’s laboratory 
(Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, 
USA). Mice were housed in individually ventilated microisolator cages 
in a specific pathogen–free facility at the University of North Caroli-
na at Chapel Hill. Mice were fed with regular chow and given water 
ad libitum on a 12-hour light/12-hour dark cycle. Mice studied were 
littermates when possible, age matched, and of both sexes, unless oth-
erwise stated in the figure legends.
RNA-Seq gene-expression analysis. RNA-Seq libraries were pre-
pared using the TruSeq RNA Sample Preparation Kit, volume 2, fol-
lowing the manufacturer’s Low-Throughput protocol (Illumina). The 
libraries were sequenced on Illumina HiSeq2500 machines by the 
University of North Carolina Functional Genomics Core. RNA-Seq 
data in FASTQ format were checked for quality using the FastQC tool 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc). The 
sequence reads in FASTQ files were mapped to human genome refer-
ence assembly hg38 and Gencode.v21 gene and transcript annotation 
using TopHat2 (71), and expression at gene level was quantified using 
Cufflinks (72). The expression values in fragments per kilobase per 
million mapped reads (or FPKM) were filtered by mean greater than 1 
among all samples and further normalized by quantile normalization, 
before log2 transformation. The log2 normalized expression data were 
used as input for differential gene-expression analysis using the Bio-
conductor package LIMMA (73), with a linear model of gene expres-
sion where the response variable of gene expression is dependent on a 
linear combination of cell code plus IL-1β treatment. Human TF gene 
annotations were downloaded from the AnimalTFDB database (74), 
current as of 12/2014, and differentially expressed TFs at a P value of 
less than 0.01 were used in hierarchical clustering analysis and heat-
map generation using the Bioconductor package Complex Heatmap 
(75). All RNA-Seq data sets were deposited in the NCBI’s Genomes 
Sequence Read Archive database (SRA PRJNA553230).
Statistics. To analyze morphometry data where multiple measure-
ments from the same individuals were made (e.g., as shown in Figure 
10), linear mixed-effects models were used with the R package nlme 
(https://cran.r-project.org/web/packages/nlme/), where the response 
variable is predicted from the fixed effect of interest (between differ-
ent groups) and the random intercept variable of individuals. The asso-
ciated P values for the fixed-effect variable of interest were estimated 
from a t distribution (76, 77). Statistical tests other than morphome-
try analysis in this manuscript were performed by Prism 7 software 
(Graphpad). Student’s t test (2 tailed, paired or unpaired, parametric 
or nonparametric) was used for comparison of statistical differences 
between 2 groups. One-way ANOVA was used to compare 3 or more 
groups, while 2-way ANOVA was used for comparing 2 or more groups 
containing 2 independent variables (e.g., HBE cell codes and infected 
lentiviruses). P values of less than 0.05 were considered statistically 
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